Cardio-Oncology’s Modern Approaches to Prevent Doxorubicin-Induced Cardiotoxicity: A Systematic Review

Cureus, Год журнала: 2024, Номер unknown

Опубликована: Авг. 5, 2024

Advances in the field of oncology have led to advent doxorubicin (DOX), an anthracycline chemotherapeutic agent, through which cancer survival rates remarkably improved. There has, however, been a rise adverse effects from use DOX, most notably cardiotoxicity. DOX-induced cardiotoxicity is thought arise generation reactive oxygen species (ROS), causing mitochondrial dysfunction cardiomyocytes. This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards focused on patients undergoing DOX therapy. The research question addressed interventions aimed at preventing Google Scholar, PubMed, ScienceDirect databases were used conduct search. Next, screening was carried out by reviewing title abstract various articles exclude irrelevant studies, retrieval full-text articles. Scale assessment narrative 2 (SANRA 2) reviews, measurement tool assess reviews (AMSTAR) checklist Cochrane risk bias randomized controlled trials (RCTs) tools employed quality assessment. provides convincing evidence about preventive counteract Primary prevention strategies against include pharmacological non-pharmacological measures. Dexrazoxane reduces without therapeutic compromise. Beta-blockers showed mixed results preserving cardiac function. renin-angiotensin-aldosterone system (RAAS) inhibitors suggests that these agents can reduce liposomal formulation decreases sacrificing effectiveness. Chemotherapy regimens should be supplemented with cardioprotective medications increase efficacy lower risks. Exercise essential strategy decreasing It acts lowering oxidative stress, maintaining function, averting apoptosis. Other antioxidative, anti-apoptotic, protective mechanisms, such as resveratrol, vitamin E, curcumin, visnagin, show promise may useful supplementary therapy during treatment. In conclusion, this highlights need multimodal incorporates different tactics, well additional strong clinical trials, ultimate goal protecting health receiving chemotherapy DOX.

Язык: Английский

Letter to Editor “Possible protective effect of rosuvastatin in chemotherapy‑induced cardiotoxicity in HER2-positive breast cancer patients: a randomized controlled trial”

Medical Oncology, Год журнала: 2024, Номер 41(11)

Опубликована: Окт. 14, 2024

Язык: Английский

Letter to the editor: Comment on “possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial”

Medical Oncology, Год журнала: 2024, Номер 41(11)

Опубликована: Окт. 14, 2024

Язык: Английский